Vorapaxar
Vorapaxar
Definition
An orally bioavailable protease-activated receptor-1 (PAR-1) antagonist, with antiplatelet activity. Upon oral administration, vorapaxar binds to PAR-1 expressed on platelets, and inhibits PAR-1-mediated platelet aggregation. Vorapaxar inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation, and does not inhibit platelet aggregation induced by adenosine diphosphate (ADP), collagen or a thromboxane mimetic.
Also known as VORAPAXAR — per NCIT
Also identified as
- ATC B01AC26 per RXNORM
- NCIT NCIT:C152912 per NCIT
- SCTID 708718003 per RXNORM
- SCTID 715596008 per RXNORM
- UNII ZCE93644N2 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Stroke | may prevent | MEDRT · Public domain (U.S. Government work) |
| Myocardial infarction | may treat | MEDRT · Public domain (U.S. Government work) |
| Peripheral arterial disease | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Heart | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculature | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Myocardium | may treat a disease of this organ | DERIVED · CC BY 4.0 |
5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.